The Patent Finder

Arrowhead Pharmaceuticals, Inc.

Also on record
Records under this name other than the patents Arrowhead Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 138 patents it holds.

Back to Arrowhead Pharmaceuticals, Inc.

PatentTitleStatus Expires Confidence
US 9,868,949Organic Compositions to Treat EPAS1-RELATED Diseases
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,040,494Rnai-Mediated Inhibition of Frizzled Related PROTEIN-1 for Treatment of Glaucoma
Term ended
Term ended Nov 7, 2026 · High confidence
Term endedTerm ended Nov 7, 2026High confidence
US 8,865,670Rnai-Related Inhibition of Tnfa Signaling Pathway for Treatment of Glaucoma
Lapsed on the fee record
Ended Oct 21, 2026 · Low confidence
Lapsed on the fee recordEnded Oct 21, 2026Low confidence
US 8,865,671RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions
Lapsed on the fee record
Ended Oct 21, 2026 · Low confidence
Lapsed on the fee recordEnded Oct 21, 2026Low confidence
US 10,081,811Organic Compositions to Treat Beta-Enac-Related Diseases
Lapsed on the fee record
Ended Sep 25, 2026 · High confidence
Lapsed on the fee recordEnded Sep 25, 2026High confidence
US 8,754,202RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
Lapsed on the fee record
Ended Jun 17, 2026 · Medium confidence
Lapsed on the fee recordEnded Jun 17, 2026Medium confidence
US 9,938,531Compositions and Methods for Inhibiting Expression of RRM2 Genes
Lapsed on the fee record
Ended Apr 10, 2026 · High confidence
Lapsed on the fee recordEnded Apr 10, 2026High confidence
US 9,932,584Interfering RNA Delivery System and Uses Thereof
Lapsed on the fee record
Ended Apr 3, 2026 · Medium confidence
Lapsed on the fee recordEnded Apr 3, 2026Medium confidence
US 8,673,873RNAi-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of cAMP-Related Ocular Disorders
Lapsed on the fee record
Ended Mar 18, 2026 · Medium confidence
Lapsed on the fee recordEnded Mar 18, 2026Medium confidence
US 8,173,617Rnai-Mediated Inhibition of Frizzled Related PROTEIN-1 for Treatment of Glaucoma
Term ended
Term ended Mar 10, 2026 · High confidence
Term endedTerm ended Mar 10, 2026High confidence
10 of 35 patents shown.
Pro members see all 35.
Pro members: see all 35 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited